Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.

The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

Microdosing GLP-1 has been touted for everything for weight management to perimenopause symptoms. But is it all it’s cracked ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...